Island Pharmaceuticals
Island Pharmaceuticals is focused on drug repurposing and clinical development for viral diseases lacking existing therapies. Their business model centers around identifying and developing solutions for unmet medical needs in the treatment of viral infections. The company aims to create value by advancing repurposed drug candidates through clinical trials and ultimately to market.
Short position
Island Pharmaceuticals (ASX:ILA) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 4 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.19% in March 2023. ILA is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Island Pharmaceuticals (ILA) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $282.7Kvs n/a (FY25)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- −$9.8Mvs n/a (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −$0.036T (source: Derived: trailing 12 months at year end)vs −$0.023 (FY25)
- Derived: trailing 12 months at year end, as at 29 Sep 2026
- Rev YoY
- n/aFY
- EPS YoY
- n/aTTM
- Derived: trailing 12 months at year end
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- 100.0%
- Operating margin
- −3,656.3%
- Net margin
- −3,482.7%
- FCF margin
- −2,008.0%
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- 24.6×
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- $108.0M
- P/E
- n/a
- P/B
- 8.0×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $282.7K | n/a | $1.3M | $11.1K |
| Gross profit | $282.7K | n/a | $1.3M | $11.1K |
| Operating income | −$10.3M | n/a | −$2.9M | −$2.9M |
| EBITDA | −$10.2M | n/a | −$2.8M | −$2.8M |
| EBIT | −$10.3M | n/a | −$2.8M | −$2.8M |
| Interest expense | n/a | n/a | $46.2K | $9.0K |
| Pretax income | −$9.8M | n/a | −$2.9M | −$2.8M |
| Tax | $0 | n/a | $0 | $0 |
| NPAT | −$9.8M | n/a | −$2.9M | −$2.8M |
| Net interest income | $276.4K | n/a | −$41.5K | −$9.0K |
| EPS basic | −$0.036T (source: Derived: trailing 12 months at year end) | −$0.023 | −$0.032 | −$0.032 |
| EPS diluted | −$0.036T (source: Derived: trailing 12 months at year end) | −$0.023 | −$0.032 | −$0.032 |
| Shares | 295.9M | n/a | 126.8M | 87.5M |
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Preliminary Final ReportAnnual Results26 Aug 2026via asx_announcements
- Annual Report to shareholdersAnnual Report26 Aug 2026via asx_announcements
- Quarterly Appendix 4C and Activities ReportQuarterly Report30 Jul 2026via asx_announcements
- Quarterly Appendix 4C and Activities ReportQuarterly Report27 Apr 2026via asx_announcements
- Appendix 4D & Half-Year Financial StatementsHalf Year Results25 Feb 2026via asx_announcements
- Quarterly Appendix 4C and Activities ReportQuarterly Report27 Jan 2026via asx_announcements
- Quarterly Appendix 4C and Activities ReportQuarterly Report30 Oct 2025via asx_announcements
- Annual Report to shareholders (incl auditor independence)Annual Report29 Aug 2025via asx_announcements
- Annual Report to shareholdersAnnual Report29 Aug 2025via asx_announcements
- Preliminary Final ReportAnnual Results29 Aug 2025via asx_announcements
Showing 10 of 27 reports